News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
News|Articles|December 30, 2024

Our Top 5 Social Media Posts of 2024

Author(s)Miranda Schmalfuhs

Check out our top five most engaged social media posts from the year 2024.

Advertisement

1.

2.

3.

4.

5.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Stock.adobe.com

Sanofi Reaches Deals with ADEL for Novel Alzheimer’s Disease Drug, Dren Bio for B-cell Depletion Therapy

ByNicholas Jacobus
December 16th 2025

Pharmaceutical Executive Daily: TrumpRx's Critical Blind Spot

ByNicholas Jacobus
December 16th 2025
Stock.adobe.com

Lunit and Daiichi Sankyo Form Collaboration to Advance Research and Discovery for AI-Driven Biomarkers and Translational Oncology

ByNicholas Jacobus
December 16th 2025
Image Credit: Adobe Stock Images/Crystal light

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

ByDavy James
December 15th 2025
Pharmaceutical Executive

Pharmaceutical Executive Daily: Retatrutide's Positive Phase III Trial Results

ByNicholas Jacobus
December 15th 2025
Advertisement
Advertisement

Trending on PharmExec

1

TrumpRX Has a Blind Spot and It Can Redefine Patient Access

2

FDA Grants National Priority Voucher to Tecvayli Combination in Relapsed or Refractory Multiple Myeloma

3

FDA Approves Enhertu Plus Perjeta as First-Line Therapy for HER2-Positive Metastatic Breast Cancer

4

Brent Saunders: Eyeing New Horizons

5

FDA Approves Lerochol for Adults with Elevated LDL Cholesterol

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us